{"disease":{"id":"eye-diseases-hereditary","name":"eye diseases hereditary"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05573984","title":"Natural History of PRPF31 Mutation-Associated Retinal Dystrophy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"PYC Therapeutics","has_results":false},{"nct_id":"NCT04765345","title":"Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Jaeb Center for Health Research","has_results":false},{"nct_id":"NCT03872479","title":"Single Ascending Dose Study in Participants With LCA10","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Editas Medicine, Inc.","has_results":false},{"nct_id":"NCT04945772","title":"Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Nanoscope Therapeutics Inc.","has_results":false},{"nct_id":"NCT03396042","title":"Natural History Study of CEP290-Related Retinal Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Editas Medicine, Inc.","has_results":false},{"nct_id":"NCT03780257","title":"Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"ProQR Therapeutics","has_results":false},{"nct_id":"NCT06852963","title":"A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"PYC Therapeutics","has_results":false},{"nct_id":"NCT04123626","title":"A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11,"lead_sponsor_name":"ProQR Therapeutics","has_results":false},{"nct_id":"NCT03913130","title":"Extension Study to Study PQ-110-001 (NCT03140969)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Laboratoires Thea","has_results":true},{"nct_id":"NCT05158296","title":"Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Laboratoires Thea","has_results":true},{"nct_id":"NCT05176717","title":"Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Laboratoires Thea","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}